maria sepulveda

🚀 We are sharing our last work! Complications, outcomes, and implications of a prolonged vegetative state in anti-NMDA receptor encephalitis: a retrospective international cohort study thelancet.com/journals/laneu…

Severe anti-NMDAR encephalitis doesn’t always mean irreversible damage. In this international study led by Josep Dalmau & Mar Guasp), ~2/3 of patients in prolonged vegetative state (≥9 months) improved—1/3 fully. Late recovery is real. #Neuroimmunology thelancet.com/journals/laneu…

El Dr Dalmau nos da su visión sobre las encefalitis autoinmunes como entidades nosológicas individuales y su impacto interdisciplinario.

Talking about IgLON5...

Let me explain IGNITION consortium's logo: Two hemispheres of the #brain 🧠. One 🚀 IGNITION rocket-antibodies against @iglon5 The other half, containing neurodegeneration. Let's solve this mistery together🔎. Apply for the #PhDposition fully funded by EU #MSCA-DN actions

A historic moment for the MOGAD community! Positive Phase III results from the METEOROID clinical trial mark the first successful MOGAD treatment study—made possible by the participants and their families. As the pre-eminent global nonprofit for #MOGAD, The MOG Project calls this a “historic day” and applauds “Hoffmann-LaRoche/Genentech’s landmark achievement and their investment in finding new, safe, and effective treatments for MOGAD.” Learn more: mogproject.org/meteoroid

We had a fruitful @ECTRIMS Winter School about NMOSD and MOGAD highlighting worldwide disparities on Ab testing and treatment access, current knowledge and the way forward. @marignierro @SaraMariottoMD @MSGazquez @MarTintore @cobo_calvo @RosaCortese5 @EoinFlanagan14 and many more

I'm looking for candidates with master degree in neuroscience interested in applying for a PFIS grant (2026 call, predoctoral position). I have a FIS project funded about demyelinating diseases👩‍⚕️. Good degree scores🤷‍♀️ mandatory😎

‼️We are sharing our last paper review:

🔊 #SaveTheDate

🔊 Mañana tendrá lugar el II Encuentro Nacional entre pacientes con #NMOSD o #MOGAD, médicos y otros profesionales especializados en su atención. 👫👭👬 Un espacio para aprender, compartir y avanzar juntos.

✨ Barcelona, the world’s hub for multiple sclerosis for some days. We are proud that our city is hosting #ECTRIMS2025, the largest international meeting in MS. An exceptional opportunity to share knowledge, highlight innovation, and strengthen our commitment to patients.

(2) patients who initially present with overlapping features of MOGAD and MS but predominantly follow an MS-like course. Read the article: neurology.org/doi/full/10.12… (2/2)

This study demonstrates 4% of children with MOG-IgG meet criteria for MS at some point during disease course. It also identifies 2 distinct clinical profiles: (1) patients who exhibit typical MS features & follow a disease trajectory indistinguishable from prototypical MS (1/2)

⏳ 2 hours to go! Casos clínicos en EM Pediátrica returns with a focus on MOGAD treatment across ages. How does management differ in children vs. adults? 📅 Today | 15:00–16:00h 🎙️ With Prof. Yael Hacohen & Dra. Maria Sepúlveda 🎤 Moderated by Dra. Georgina Arrambide 🔗 bit.ly/CCEMP_2025 #MOGAD #Neuroinmunología #EsclerosisMúltiple

Dr Eugenia Martínez in the controversy session about testing for the diagnosis of autoimmune encephalitis at #ean25 @EANeurology

💡 We have developed a new mouse model for anti-NMDAR encephalitis will indeed deepen the understanding of the disease's pathophysiology and potentially accelerate treatment discovery.

Celebraremos la XV reunión anual de pacientes de EM con la Unidad de Neuroinmunología del Hospital Clinic para conmemorar el día Mundial de la EM

@neuroimmuclinic ➡️Imatge avançada en malalties neuroimmunològiques (ImaginEM)⬅️ @SaraLlufriu 👉f.mtr.cool/gefzqajhqo

Revisaremos las ventajas de la investigación básica aplicada a la práctica clínica de la #EsclerosisMúltiple, #NMOSD y #MOGAD 🧠 ⚡️